首页> 外文期刊>Journal of Clinical Epidemiology >AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program.
【24h】

AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program.

机译:AHRQ系列论文4:比较医疗干预措施时评估危害:AHRQ和有效的医疗保健计划。

获取原文
获取原文并翻译 | 示例
           

摘要

Comparative effectiveness reviews (CERs) are systematic reviews that evaluate evidence on alternative interventions to help clinicians, policy makers, and patients make informed treatment choices. Reviews should assess harms and benefits to provide balanced assessments of alternative interventions. Identifying important harms of treatment and quantifying the magnitude of any risks require CER authors to consider a broad range of data sources, including randomized controlled trials (RCTs) and observational studies. This may require evaluation of unpublished data in addition to published reports. Appropriate synthesis of harms data must also consider issues related to evaluation of rare or uncommon events, assessments of equivalence or noninferiority, and use of indirect comparisons. This article presents guidance for evaluating harms when conducting and reporting CERs. We include suggestions for prioritizing harms to be evaluated, use of terminology related to reporting of harms, selection of sources of evidence on harms, assessment of risk of bias (quality) of harms reporting, synthesis of evidence on harms, and reporting of evidence on harms.
机译:比较有效性评估(CER)是系统的评估,用于评估有关替代干预措施的证据,以帮助临床医生,政策制定者和患者做出明智的治疗选择。审查应评估危害和利益,以平衡评估其他干预措施。要确定治疗的重大危害并量化任何风险的程度,CER作者需要考虑广泛的数据来源,包括随机对照试验(RCT)和观察性研究。除已发布的报告外,这可能还需要评估未发布的数据。危害数据的适当综合还必须考虑与罕见或罕见事件的评估,等价或非劣等的评估以及间接比较的使用有关的问题。本文介绍了在进行和报告CER时评估危害的指南。我们提供的建议包括:对要评估的危害进行优先排序,使用与危害报告相关的术语,选择危害证据的来源,评估危害报告的偏倚(质量)风险,危害证据的综合以及关于危害证据的报告危害

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号